Targeted Alpha Radiopharmaceutical Therapy and Key Considerations for Nuclear Medicine Technologists

Area of Science:

• Nuclear medicine
• Oncology
• Radiopharmaceutical therapy

Background:

• Targeted radiopharmaceutical therapy (RPT) integrates imaging and therapy for cancer treatment.
• Alpha-emitting radionuclides offer high precision for targeting single tumor cells.

Purpose of the Study:

• To provide a comprehensive overview of advancements in targeted alpha therapy (TAT).
• To discuss relevant clinical trials and logistical considerations for TAT in oncology.

Main Methods:

• Review of current literature on targeted alpha therapy.
• Analysis of clinical trials involving alpha-emitting radionuclides.
• Examination of logistical and radiation safety aspects of TAT administration.

Main Results:

• ²²³Ra-dichloride is the only FDA-approved TAT for castration-resistant prostate cancer.
• Multiple clinical trials are progressing with radionuclides like ²²³Ra, ²²⁵Ac, ²¹¹At, ²¹²Pb, and ²²⁷Th.
• Increasing use of TAT necessitates attention to administration logistics and safety protocols.

Conclusions:

• Targeted alpha therapy is a rapidly advancing field in nuclear medicine and oncology.
• The development of new TATs is imminent, with significant clinical trial activity.
• Logistical and safety considerations are crucial for the widespread adoption of TAT.